EffRx signs distribution agreement with Ahn-Gook Pharma for Binosto® for Korea

EffRx signs distribution agreement with Ahn-Gook Pharma for Binosto® for Korea

Freienbach, 03 June 2013 – EffRx Pharmaceuticals S.A. today announces the signing of an exclusive distribution agreement with...
BINOSTO® Featured on Two National Programs in United States

BINOSTO® Featured on Two National Programs in United States

Satellite radio’s “ReachMD,” and the “Balancing Act” on Lifetime Television Focus on Breakthrough Treatment for Osteoporosis and...
BIO-Europe Spring 2013

BIO-Europe Spring 2013

Meet the Effrx team at the 7th Annual Int'l Partnering Conference Bio-Europe Spring 2013 in Barcelona, Spain on March 11 - 13...
 

Welcome to EffRx Pharmaceuticals S.A.

Dedicated to Improve Pharmaceutical Products

EffRx Pharmaceuticals SA is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential. Once developed, we partner these products with established pharmaceutical companies. Our goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying our technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action.

Thereby generating better products for patients in a cost effective manner. The lead product, Steovess® (70mg Alendronate) for the treatment of osteoporosis has been accepted for national approvals in the European Union (DCP) in December 2011. Approval for the same drug in the US under the brand name Bionosto® has been granted by the FDA in March 2012. Bionosto® is being sold in the US by Mission Pharmacal since October 1st 2012. EffRx is actively seeking partnerships for the distribution of Binosto®/Steovess® in other regions of the world.

 

 

BINOSTO® Featured on Two National Programs in United States 

May 15, 2013

Satellite radio’s “ReachMD,” and the “Balancing Act” on Lifetime Television Focus on Breakthrough Treatment for Osteoporosis and Patients Who Have Difficulty Swallowing Pills.

 
 

EffRx signs distribution agreement with Ahn-Gook Pharma 

Freienbach, 03 June 2013

EffRx Pharmaceuticals S.A. today announces the signing of an exclusive distribution agreement with Ahn-Gook Pharmaceutical Co. Ltd for Binosto - EffRx’s innovative osteoporosis medication - for the Korean market.